Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in a ten-year-old girl accompanied by posterior reversible encephalopathy syndrome and disseminated herpes simplex virus infection by 板倉 隆太 et al.
Epstein-Barr virus-associated hemophagocytic
lymphohistiocytosis in a ten-year-old girl
accompanied by posterior reversible
encephalopathy syndrome and disseminated
herpes simplex virus infection
journal or
publication title
Journal of Saitama Medical University
volume 41
number 2
page range 139-143
year 2015-03-31
URL http://id.nii.ac.jp/1386/00000522/
Creative Commons : 表示 - 非営利 - 改変禁止
http://creativecommons.org/licenses/by-nc-nd/3.0/deed.ja
139
＊ Author : Department of Pediatrics, Saitama Medical Center, Saitama 
Medical University
1981, Kamoda, Kawagoe, Saitama 350 -8550, Japan
◯ The authors declare that there are no conflicts of interest associated 
with the present study.
埼玉医科大学雑誌　第 41 巻　第 2 号　平成 27 年 3 月
Case Report
Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis 
in a ten-year-old girl accompanied by posterior reversible encephalopathy 
syndrome and disseminated herpes simplex virus infection
Ryuta Itakura＊, Fumihiko Namba, Ayumu Arakawa,
Yoshitaka Asano, Koichi Moriwaki, Masanori Tamura
Department of Pediatrics, Saitama Medical Center, Saitama Medical University
　Posterior reversible encephalopathy syndrome (PRES) has become a common disease entity. Clinically, the 
patient usually presents with acute onset of neurological problems including headache, convulsions and visual 
impairment or blindness. On the other hand, disseminated herpes simplex virus (HSV)-1 infection is usually 
observed in immunocompromised individuals. We present a case of cyclosporin A (CyA)-induced PRES and 
disseminated HSV-1 infection during chemotherapy treatment with etoposide, prednisolone and CyA for Epstein-
Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH). The combination therapy for EBV-HLH 
was initially effective. However, the patient developed prominent side effects, drug-induced encephalopathy and the 
risk of infection under an immunosuppressive state. She showed an excellent outcome after discontinuation of CyA 
and treatment with acyclovir and methylprednisolone. In conclusion, this case report emphasizes the difficulty in 
choosing an appropriate treatment for EBV-HLH when some side effects develop and the importance of making a 
timely diagnosis for preventing progression to permanent damage from HLH-associated encephalopathy or PRES. 
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Introduction
　Posterior reversible encephalopathy syndrome 
(PRES) has become a common disease entity. 
Clinically, the patient usually presents with acute 
onset of neurological problems including headache, 
convulsions and visual impairment or blindness. 
The disease may be reversed by initiation of an 
appropriate treatment; therefore, it is important to 
make a timely diagnosis to prevent progression to 
permanent damage. Disseminated herpes simplex 
virus (HSV)-1 infection is rare and can predominantly 
be seen in immunocompromised individuals like 
neonates, patients with hemato-oncologic malignancies, 
transplant recipients, or due to immunosuppressive 
medication. Despite use of advanced diagnostic 
methods and antiviral therapy, this disease continues 
to have high morbidity and mortality. We present a 
case of Epstein Barr virus-associated hemophagocytic 
lymphohistiocytosis (EBV-HLH) accompanied by 
cyclosporin A (CyA)-induced PRES and disseminated 
HSV-1 infection.
Case Report
A 10-year-old girl with no family history of HLH was 
admitted to the Pediatrics inpatient unit of our hospital 
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with continuous fever and swollen cer vical lymph 
nodes. She was transferred from a primary care center 
because her fever could not be controlled even after 
administration of oral antibiotics for 3 days. Besides 
asthma, which was well controlled, the patient had no 
other known medical problems or family history of 
specific diseases.
On admission, she was conscious but not physically 
active. An oral cavity examination revealed a congested 
and red pharynx with white patches on her tonsils. 
Her skin, abdominal and genital findings were normal. 
A maximum temperature of 40.2 ℃ was recorded 
per axilla. Her heart rate was 130 beats/min and her 
SpO2 was 96% on room air. She had bilateral swollen 
lymph nodes (1.5 cm) in the neck region, with 
tenderness. Her total WBC count was 10,500 cells/
mm3, and she tested negative for group A streptococci, 
adenoviruses and cytomegalovirus. Her serum was 
positive for EBV viral capsid antigen immunoglobulin 
M (IgM) (>1.0) and negative for EBV nuclear antigen 
(<0.5). A presumptive diagnosis of acute infectious 
mononucleosis was made and a wait-and-see approach 
was adopted (Fig. 1). Because the platelet counts 
decreased to 90,000 cells/mm3, bone marrow aspiration 
was per formed on the day 4, which demonstrated 
hemophagocytosis by macrophages (Fig. 2). The 
patient met the diagnostic criteria for HLH. The EBV 
DNA load in peripheral blood mononuclear cells 
(PBMCs) was 9.4×104 copies/106 cells, and her serum 
ferritin levels increased to 1,302 ng/ml on the day 
4. After the diagnosis of EBV-HLH, a combination 
therapy with prednisolone (PSL) at 2 mg/kg/day and 
CyA at 3 mg/kg/day was initiated. Etoposide (VP-16) 
at 150 mg/m2 twice a week was added on the day 15 
because the PSL/CyA therapy was not effective. On 
the day 19, a generalized vesicular eruption developed 
and the administration of acyclovir (ACV) 30 mg/kg/
day was initiated (Fig. 1). Subsequently, the patient 
was diagnosed with disseminated HSV infection and 
herpetic keratoconjunctivitis by the detection of HSV 
in the serum using PCR (4.0×106 copies/106 cells), and 
VP-16 was discontinued because of its bone marrow 
depressant effects.
　On the day 29, the patient developed seizures and 
was administered diazepam followed by phenobarbital. 
Serum sodium, potassium, and calcium levels were 
133 mEq/L, 3.6 mEq/L, and 8.5 mg/dL, respectively. 
Serum CyA level in continuous intravenous infusion 
Fig. 1. Scheme of clinical course in this case. ACV, acyclovir; CyA, cyclosporine A; MCFG, micafungin; MINO, minocycline; 
mPSL, methylpredonisolone; PAPM/BP, panipenem/betamipron; PSL, prednisolone; SBT/ABPC, sulbactam/ampicillin; 
TAZ/PIPC, tazobactam/piperacillin; VP-16, etoposide.
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was 101.6 ng/mL. Her blood pressure was elevated 
to 168/118 mmHg. A presumptive diagnosis of PRES 
induced by CyA, central nervous system symptoms 
of EBV-HLH or herpes simplex encephalitis was 
made. Consequently, CyA was discontinued, whereas 
ACV was continued. In addition, methylprednisolone 
(mPSL) pulse therapy was initiated. Brain MRI showed 
a high intensity signal on T2WI, DWI, and ADC-map 
in the subcortical white matter and cortex within the 
right parietal, temporal and occipital lobes (Fig. 3a, 
3b, and 3c, respectively). No mass, hemorrhage or 
hydrocephalus was noted. The cerebrospinal fluid (CSF) 
was clear and <1 WBC/mm3; CSF was also negative 
for HSV DNA (<1.0 ×102 copies/106 cells). An EEG 
showed no slow wave or epileptic discharge, indicating 
no evidence of encephalitis or encephalopathy. The 
antiseizure medications were titrated down over the 
next 2 weeks. On the day 43, the high intensity signal 
on T2WI disappeared (Fig. 3d). A provisional diagnosis 
of PRES was made. Exacerbation of EBV-HLH after the 
discontinuation of CyA was not observed. After a long 
Fig. 2. Day 4 bone marrow examination showing a reduction 
of the cellularity in all lineages. Macrophages were 
increased with signs of hemmophagocytosis.
Fig. 3. a-c) Day 29 MRI of brain showing a high intensity signal on T2WI (a), DWI (b), and ADC-map (c) in the subcortical 
white matter and cortex within the right parietal, temporal and occipital lobes (white arrow). d) Day 43 MRI of brain 
showing no high intensity signal on T2WI.
stay in the hospital, the patient returned to her normal 
status. 
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Discussion
HLH is a potentially fatal condition because of 
dysregulated lymphocyte activation and proliferation 
that is mainly characterized by impaired or inactive 
NK and cytotoxic T cells, leading to macrophage 
hyperactivation and cytokine overexpression1). HLH is 
frequently fatal if not treated promptly. HLH treatment is 
based on the control of the cytokine storm and cellular 
proliferation. In par ticular, immunochemotherapy, 
as proposed by the Histiocyte Society, consists of 
a combination therapy with VP-16, dexamethasone 
and CyA2). The prompt use of VP-16 greatly improves 
the outcome3) and the use of CyA has been reported 
to reduce the rate of fatal infections associated with 
neutropenia4).
　We have repor ted a case of EBV-HLH that was 
treated with a combination of VP-16, PSL and CyA. 
This combination therapy was ef fective. Disease 
progression, such as prolonged fever and abnormal 
laboratory values, was well controlled. However, the 
patient suffered complications caused by disseminated 
HSV-1 infection, herpetic keratoconjunctivitis and 
PRES. On reviewing the literature, we found that 
although these immunomodulating chemotherapies 
are ef fective, they are also commonly associated 
with side effects. Most side effects worsen following 
a prolonged course of treatment5). Specifically, CyA 
is associated with severe headache, hyper tension, 
seizures and renal impairment. PSL has many well-
described adverse effects, including hyperglycemia, 
fluid retention, hypertension and weight gain. VP-16 
is associated with myelosuppression and development 
of secondar y leukemia. Therefore, a combination 
therapy with VP-16, PSL and CyA for HLH should be 
carefully performed while monitoring the side effects, 
par ticularly the risk of developing disseminated 
infection under long-term immunosuppression and 
drug-induced encephalopathy.
PRES is a transient clinicoradiologic phenomenon 
characterized by seizures, headache, altered mental 
status and visual impairment with abnormal signal 
lesions on MRI. Since it was first proposed in 1996 by 
Hinchey, et al.6), PRES has been reported in various 
conditions and has developed in association with the 
use of medications such as chemotherapeutic agents, 
immunosuppressive drugs, immunoglobulins and 
antiangiogenic drugs7 -9). Significant neurological 
toxicity, which is proposed to be PRES, has been 
reported during treatment with the HLH-2004 protocol 
from the Histiocyte Society10). Because HLH is a rare 
multisystem disorder in which the occurrence of PRES 
is even rarer, it can be dif ficult to distinguish PRES 
from other neurological manifestations such as central 
ner vous system symptoms of EBV-HLH or herpes 
simplex encephalitis. Lee and colleagues compared the 
clinical and laboratory findings at the development of 
PRES between HLH patients with and without PRES 
to determine the putative risk factors. Among the 
several factors, preceding hypertension, a preceding 
rise in ferritin level >50% compared with 1 week before 
development of PRES, and hyponatremia (<135 mEq/L) 
were statistically significant, indicating that these 
factors apparently comprise putative risk factors for 
PRES complicated during induction chemotherapy10). 
The present case did not show any risk factors for 
PRES at the development of seizures except mild 
hyponatremia (serum sodium: 133 mEq/L). In the 
present case, it was difficult to choose an appropriate 
treatment for EBV-HLH accompanied by PRES and 
HSV-1 infection, because of the following reasons: (1) 
treatment for PRES, which involves discontinuation 
of CyA, is opposite to the treatment for EBV-HLH 
itself and (2) diagnosis of herpes simplex encephalitis 
requires isolation and identification of HSV-1 DNA from 
CSF by PCR, which takes a few days. However, careful 
dif ferential diagnosis of these neurologically toxic 
conditions from other causes of neurological conditions 
was done and permanent damage to the affected brain 
tissues was eventually prevented. mPSL pulse therapy 
was alternatively given instead of CyA to prevent 
exacerbations of HLH and used in the treatment of 
acute viral encephalitis because the diagnosis of herpes 
simplex encephalitis had not yet been excluded at that 
time.
　In summar y,  we repor t  a  case of  PRES and 
disseminated HSV-1 infection during multi-agent 
chemotherapy for EBV-HLH. Our case highlights 
the need for physicians to pay adequate attention 
to the side ef fects of combination chemotherapies 
for HLH and to make a timely diagnosis to prevent 
progression to permanent damage from HLH-associated 
encephalopathy or PRES.
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可逆性後頭葉白質脳症と播種性ヘルペス感染症を合併したEBウイルス関連血球貪食症候群の 1 例
板倉隆太，難波文彦，荒川歩，浅野祥孝，森脇浩一，田村正徳
　可逆性後頭葉白質脳症は通常臨床的には頭痛・痙攣・視覚障害等の神経症状で発症するしばしば認める疾患
である．一方，播種性ヘルペス感染症は免疫不全患者で認める感染症である．今回我々は，EBウイルス関連
血球貪食症候群に対するエトポシド・プレドニゾロン・シクロスポリンを用いた多剤併用化学療法中に，シク
ロスポリン関連可逆性後頭葉白質脳症と播種性ヘルペス感染症と診断された10歳女児を経験したので報告する．
EBウイルス関連血球貪食症候群に対する併用療法は当初有効であったが，薬剤関連脳症と免疫抑制下での全身
性感染症発症という重篤な合併症を認めた．シクロスポリン中止とアシクロビル・メチルプレドニゾロン投与
により速やかな症状の回復を認めた．以上，本症例により，①有害事象が生じた際のEBウイルス関連血球貪食
症候群に対する適切な治療法選択の難しさと，②血球貪食症候群関連脳症または可逆性後頭葉白質脳症による
後遺症を回避するために早期診断が重要と考えられた．
埼玉医科大学　総合医療センター　小児科　〒 350 - 8550 埼玉県川越市鴨田 1981
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